SFDA Penalizes Wandashan Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
China's State FDA released its latest report on the lethal Ciwujia herbal injection produced by Wandashan Pharmaceutical, concluding that the incident is a severe adverse reaction caused by bacteria. According to investigation, the particular batch of Ciwujia was soaked by rain water leading to contamination, but the company's sales person in Yunnan changed the packaging labels and sold the product. SFDA concluded that Wandashan Pharmaceutical violated the Drug Administration Law and demanded the Heilongjiang FDA to suspend the company's production and withdraw its GMP authentication. Furthermore, Wandashan Pharmaceutical will be penalized in accordance with the relevant laws. Personnel responsible for the incident will be banned from drug production and distribution for 10 years. (Click here for more - Chinese Language)
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.